Latest Facebook Post from IMU, page-19

Thanks to all posters for recent IMU updates & nice to see some decent Pharma media coverage. Some very encouraging news there moving forward & happy to see Ph1 trials being conducted in the USA & Australia for PD1-Vaxx in non small cell lung Ca.

I can’t explain the SP either on this news, particularly that we are expecting Ph2 Her-Vaxx results this year & with some hot items in our pipeline & a very professional & world renowned team.

Things have run so smoothly through FDA applications, GMP manufacturing & so far in the clinic, except for a minor hiccup much earlier on in Her-Vaxx Ph1 with shelf life stability of vaccines. You have to expect these things in INDs, but this was addressed swiftly & professionally.

The team of scientists, medical advisors & management IMU have onboard gives me a lot of confidence that what they have in their pipeline will be given every chance of succeeding through well designed & managed clinical trials, with much experience behind that & the ability to attract funding to achieve this. This appears to be half the battle for many biotechs, even if what they have in their IP is very promising.

GLTAH & well done team IMU